A phase I, first-in-human study of TAK-164, an antibody-drug conjugate, in patients with advanced gastrointestinal cancers expressing guanylyl cyclase C.
Richard D KimAlexis D LealAparna ParikhDavid P RyanShining WangBrittany BahamonNeeraj GuptaAaron MossJoanna PyeHarry MiaoHaig InguilizianJames M ClearyPublished in: Cancer chemotherapy and pharmacology (2023)
NCT03449030.